EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
The observations are procedural in nature and will be responded to within the stipulated time
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Subscribe To Our Newsletter & Stay Updated